Bristol Myers' Investigational Lung Cancer Candidate Shows High Response Rates
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb & Co (NYSE:BMY) announced updated results from a TRIDENT-1 study, showing that repotrectinib, a next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), continued to show high response rates and durable responses in patients with metastatic non-small cell lung cancer. The U.S. FDA accepted the New Drug Application for repotrectinib and granted Priority Review. The study remains ongoing to assess long-term outcomes and additional endpoints.
August 16, 2023 | 4:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's repotrectinib shows promising results in TRIDENT-1 study, which could potentially lead to a new treatment option for metastatic non-small cell lung cancer. The FDA has granted Priority Review for the drug.
The positive results from the TRIDENT-1 study and the FDA's Priority Review status for repotrectinib indicate a strong potential for the drug's approval and subsequent market launch. This could lead to increased revenues for Bristol Myers Squibb, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100